Skip to main content
. Author manuscript; available in PMC: 2016 Nov 15.
Published in final edited form as: Bioorg Med Chem. 2015 Oct 11;23(22):7119–7130. doi: 10.1016/j.bmc.2015.09.050

Figure 7.

Figure 7

Western blot analysis of H1650 cells treated with gefitinib, C′ dot-(Cy5)-PEG-Phe-Arg-dPEG2APdMG (NDC 6), and C′ dot-(Cy5)-PEG-Phe-Lys-PABC-APdMG (NDC 7). Cells treated with gefitinib or specified NDC at indicated concentrations for 18 hrs followed by EGF (50 ng/mL) for 5 minutes. (pEGFR – phosphorylated EGFR; tEGFR – total EGFR)